{"id":357365,"date":"2026-11-20T10:55:07","date_gmt":"2026-11-20T05:25:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=357365"},"modified":"2026-11-20T10:55:07","modified_gmt":"2026-11-20T05:25:07","slug":"sun-pharma-vs-dr-reddys-q2-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/","title":{"rendered":"Sun Pharma vs Dr Reddy&#8217;s 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High"},"content":{"rendered":"<div style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;margin:0 0 16px;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:14px;\">\n<tr>\n<th style=\"text-align:left;padding:4px 10px;\">Sun Pharma vs Dr Reddy&#x27;s at a glance<\/th>\n<th style=\"text-align:left;padding:4px 10px;\">Sun Pharmaceutical Industries<\/th>\n<th style=\"text-align:left;padding:4px 10px;\">Dr. Reddy&#x27;s Laboratories<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Share price (19 Nov 2026)<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 1,900.00<\/td>\n<td style=\"padding:4px 10px;\">Rs 1,400.90<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Market cap<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 4,56,593 crore<\/td>\n<td style=\"padding:4px 10px;\">Rs 1,16,771 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>P\/E ratio<\/strong><\/td>\n<td style=\"padding:4px 10px;\">41.56<\/td>\n<td style=\"padding:4px 10px;\">42.31<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Q2 FY27 net profit<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 2,002 crore<\/td>\n<td style=\"padding:4px 10px;\">Rs 913.2 crore<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Sun Pharma vs Dr Reddy&#x27;s compares India&#8217;s largest drugmaker with one of its most global generic companies after a weak quarter for both. In Q2 FY27, Sun Pharma&#8217;s revenue rose 11.8% to Rs 16,716 crore but net profit fell 36.2% to Rs 2,002 crore. Dr Reddy&#8217;s revenue slipped 3.3% to Rs 8,854 crore and net profit fell 31.7% to Rs 913 crore. Both trade at a P\/E near 42, but Sun Pharma&#8217;s ROE of 13.79% is almost twice Dr Reddy&#8217;s 7.21%.<\/p>\n<\/div>\n<p><strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> in 2027 looks unusual on the numbers: both companies reported a September quarter profit fall of <strong>more than 30%<\/strong>, yet Dr Reddy&#8217;s share price sits <strong>within 1% of its 52-week high<\/strong> and Sun Pharma is about 7% below its own. The <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> Q2 results show why the market reads each fall differently.<\/p>\n<p>Both are <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> pharma heavyweights. Sun Pharmaceutical Industries is valued at about Rs 4,56,593 crore and Dr. Reddy&#8217;s Laboratories at about Rs 1,16,771 crore. This <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> guide compares their business mix, valuation, <strong>Q2 FY27 results<\/strong>, outlook, risks and shareholding.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=sun-pharma-vs-dr-reddys-q2-results\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_vs_Dr_Reddys_Company_Overview\" title=\"Sun Pharma vs Dr Reddy&#8217;s: Company Overview\">Sun Pharma vs Dr Reddy&#8217;s: Company Overview<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#What_Sun_Pharmaceutical_Industries_Does\" title=\"What Sun Pharmaceutical Industries Does\">What Sun Pharmaceutical Industries Does<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#What_Dr_Reddys_Laboratories_Does\" title=\"What Dr. Reddy&#x27;s Laboratories Does\">What Dr. Reddy&#x27;s Laboratories Does<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#How_Sun_Pharma_and_Dr_Reddys_Make_Money\" title=\"How Sun Pharma and Dr Reddy&#8217;s Make Money\">How Sun Pharma and Dr Reddy&#8217;s Make Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_vs_Dr_Reddys_Valuation_and_Key_Metrics\" title=\"Sun Pharma vs Dr Reddy&#8217;s Valuation and Key Metrics\">Sun Pharma vs Dr Reddy&#8217;s Valuation and Key Metrics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_vs_Dr_Reddys_Q2_FY27_Results\" title=\"Sun Pharma vs Dr Reddy&#8217;s Q2 FY27 Results\">Sun Pharma vs Dr Reddy&#8217;s Q2 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_vs_Dr_Reddys_Outlook_After_the_Q2_Results\" title=\"Sun Pharma vs Dr Reddy&#8217;s Outlook After the Q2 Results\">Sun Pharma vs Dr Reddy&#8217;s Outlook After the Q2 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_specialty_growth_and_margins\" title=\"Sun Pharma: specialty growth and margins\">Sun Pharma: specialty growth and margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Dr_Reddys_rebuilding_after_a_product_cycle\" title=\"Dr Reddy&#8217;s: rebuilding after a product cycle\">Dr Reddy&#8217;s: rebuilding after a product cycle<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Risks_in_Sun_Pharma_vs_Dr_Reddys\" title=\"Risks in Sun Pharma vs Dr Reddy&#8217;s\">Risks in Sun Pharma vs Dr Reddy&#8217;s<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Risks_for_Sun_Pharmaceutical_Industries\" title=\"Risks for Sun Pharmaceutical Industries\">Risks for Sun Pharmaceutical Industries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Risks_for_Dr_Reddys_Laboratories\" title=\"Risks for Dr. Reddy&#x27;s Laboratories\">Risks for Dr. Reddy&#x27;s Laboratories<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_vs_Dr_Reddys_Shareholding\" title=\"Sun Pharma vs Dr Reddy&#8217;s Shareholding\">Sun Pharma vs Dr Reddy&#8217;s Shareholding<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Which_Investor_Does_Each_Pharma_Stock_Suit\" title=\"Which Investor Does Each Pharma Stock Suit?\">Which Investor Does Each Pharma Stock Suit?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Sun_Pharma_suits_investors_who_want_specialty-led_growth\" title=\"Sun Pharma suits investors who want specialty-led growth\">Sun Pharma suits investors who want specialty-led growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Dr_Reddys_suits_investors_betting_on_a_launch-led_recovery\" title=\"Dr Reddy&#8217;s suits investors betting on a launch-led recovery\">Dr Reddy&#8217;s suits investors betting on a launch-led recovery<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Final_View_on_Sun_Pharma_vs_Dr_Reddys\" title=\"Final View on Sun Pharma vs Dr Reddy&#8217;s\">Final View on Sun Pharma vs Dr Reddy&#8217;s<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#FAQs_on_Sun_Pharma_vs_Dr_Reddys\" title=\"FAQs on Sun Pharma vs Dr Reddy&#8217;s\">FAQs on Sun Pharma vs Dr Reddy&#8217;s<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Why_did_Sun_Pharmas_profit_fall_in_Q2_FY27\" title=\"Why did Sun Pharma&#x27;s profit fall in Q2 FY27?\">Why did Sun Pharma&#x27;s profit fall in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Why_is_Dr_Reddys_stock_near_its_52-week_high_after_weak_results\" title=\"Why is Dr Reddy&#x27;s stock near its 52-week high after weak results?\">Why is Dr Reddy&#x27;s stock near its 52-week high after weak results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Which_pharma_stock_has_the_higher_ROE\" title=\"Which pharma stock has the higher ROE?\">Which pharma stock has the higher ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#What_is_the_PE_of_Sun_Pharma_and_Dr_Reddys\" title=\"What is the P\/E of Sun Pharma and Dr Reddy&#x27;s?\">What is the P\/E of Sun Pharma and Dr Reddy&#x27;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#How_big_are_Sun_Pharma_and_Dr_Reddys\" title=\"How big are Sun Pharma and Dr Reddy&#x27;s?\">How big are Sun Pharma and Dr Reddy&#x27;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Who_owns_Sun_Pharma_and_Dr_Reddys\" title=\"Who owns Sun Pharma and Dr Reddy&#x27;s?\">Who owns Sun Pharma and Dr Reddy&#x27;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-vs-dr-reddys-q2-results\/#Is_Sun_Pharma_vs_Dr_Reddys_a_buy_or_sell_decision\" title=\"Is Sun Pharma vs Dr Reddy&#x27;s a buy or sell decision?\">Is Sun Pharma vs Dr Reddy&#x27;s a buy or sell decision?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_vs_Dr_Reddys_Company_Overview\"><\/span><strong>Sun Pharma vs Dr Reddy&#8217;s: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Sun_Pharmaceutical_Industries_Does\"><\/span><strong>What Sun Pharmaceutical Industries Does<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharmaceutical Industries is India&#8217;s largest pharmaceutical company and a leading generic and <strong>specialty<\/strong> drugmaker in the US. Its specialty portfolio, led by dermatology and other branded products, has become a large share of its global earnings. Promoters hold 52.68%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_Dr_Reddys_Laboratories_Does\"><\/span><strong>What Dr. Reddy&#x27;s Laboratories Does<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr. Reddy&#8217;s Laboratories, based in Hyderabad, makes generic medicines, active pharmaceutical ingredients and branded drugs for India, the US, Russia and other markets. Its promoter group holds 26.63%, and institutions own most of the rest.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Sun_Pharma_and_Dr_Reddys_Make_Money\"><\/span><strong>How Sun Pharma and Dr Reddy&#8217;s Make Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Both earn from branded generics in India, generic drugs in the US and other export markets, and bulk drug sales. Profit depends heavily on the US, where a few high-value products can lift or cut margins sharply.<\/p>\n<p>The key difference in <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> is mix. Sun Pharma earns a growing share from patented <strong>specialty<\/strong> brands, which carry steadier pricing. Dr Reddy&#8217;s relies more on generics, where prices fall once competition arrives, so its profit swings more with individual product cycles.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_vs_Dr_Reddys_Valuation_and_Key_Metrics\"><\/span><strong>Sun Pharma vs Dr Reddy&#8217;s Valuation and Key Metrics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>These figures use the 19 November 2026 close and trailing twelve month ratios.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Sun Pharma vs Dr Reddy&#x27;s metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr. Reddy&#x27;s Laboratories<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share price (CMP)<\/td>\n<td>Rs 1,900.00<\/td>\n<td>Rs 1,400.90<\/td>\n<\/tr>\n<tr>\n<td>52-week high<\/td>\n<td>Rs 2,046.90<\/td>\n<td>Rs 1,414.90<\/td>\n<\/tr>\n<tr>\n<td>52-week low<\/td>\n<td>Rs 1,583.70<\/td>\n<td>Rs 1,101.00<\/td>\n<\/tr>\n<tr>\n<td>Distance from 52-week high<\/td>\n<td>-7.2%<\/td>\n<td>-1.0%<\/td>\n<\/tr>\n<tr>\n<td>Market capitalisation<\/td>\n<td>Rs 4,56,593 crore<\/td>\n<td>Rs 1,16,771 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E ratio (TTM)<\/td>\n<td>41.56<\/td>\n<td>42.31<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>40.13<\/td>\n<td>40.13<\/td>\n<\/tr>\n<tr>\n<td>P\/B ratio<\/td>\n<td>5.11<\/td>\n<td>3.01<\/td>\n<\/tr>\n<tr>\n<td>Return on equity (ROE)<\/td>\n<td>13.79%<\/td>\n<td>7.21%<\/td>\n<\/tr>\n<tr>\n<td>Debt to equity<\/td>\n<td>0.04<\/td>\n<td>0.19<\/td>\n<\/tr>\n<tr>\n<td>Dividend yield<\/td>\n<td>0.84%<\/td>\n<td>0.57%<\/td>\n<\/tr>\n<tr>\n<td>FY26 revenue<\/td>\n<td>Rs 61,674 crore<\/td>\n<td>Rs 35,059 crore<\/td>\n<\/tr>\n<tr>\n<td>FY26 net profit<\/td>\n<td>Rs 11,565 crore<\/td>\n<td>Rs 4,158 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> table shows near-identical earnings multiples, with Sun Pharma at a <strong>P\/E of 41.56<\/strong> and Dr Reddy&#8217;s at 42.31. The pharma industry <strong>P\/E<\/strong> is 40.13, so both trade slightly above the sector.<\/p>\n<p>Sun Pharma has the higher <strong>return on equity<\/strong> at 13.79% against 7.21%, and a higher P\/B of 5.11 against 3.01. Both carry little debt.<\/p>\n<p>Dr Reddy&#8217;s at Rs 1,400.90 is only about 1.0% below its <strong>52-week high<\/strong> of Rs 1,414.90. Sun Pharma at Rs 1,900 is about 7.2% below its high of Rs 2,046.90.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_vs_Dr_Reddys_Q2_FY27_Results\"><\/span><strong>Sun Pharma vs Dr Reddy&#8217;s Q2 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Figures below are consolidated revenue and <strong>net profit<\/strong> for the quarter ended 30 September 2026.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Sun Pharma vs Dr Reddy&#x27;s Q2 FY27 (Sep 2026 quarter)<\/th>\n<th>Sun Pharmaceutical Industries<\/th>\n<th>Dr. Reddy&#x27;s Laboratories<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue Q2 FY27<\/td>\n<td>Rs 16,716 crore<\/td>\n<td>Rs 8,854 crore<\/td>\n<\/tr>\n<tr>\n<td>Revenue Q2 FY26<\/td>\n<td>Rs 14,948 crore<\/td>\n<td>Rs 9,152 crore<\/td>\n<\/tr>\n<tr>\n<td>Revenue change YoY<\/td>\n<td>+11.8%<\/td>\n<td>-3.3%<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q2 FY27<\/td>\n<td>Rs 2,002 crore<\/td>\n<td>Rs 913.2 crore<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q2 FY26<\/td>\n<td>Rs 3,137 crore<\/td>\n<td>Rs 1,337 crore<\/td>\n<\/tr>\n<tr>\n<td>Net profit change YoY<\/td>\n<td>-36.2%<\/td>\n<td>-31.7%<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q1 FY27<\/td>\n<td>Rs 2,911 crore<\/td>\n<td>Rs 435.6 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In the <strong>Q2 FY27 results<\/strong>, Sun Pharma&#8217;s revenue rose 11.8% to Rs 16,716 crore, but <strong>net profit<\/strong> fell 36.2% to Rs 2,001.6 crore. Its <strong>operating margin<\/strong> dropped to 24.8% from 34.7%, and profit was also below the Rs 2,910.8 crore of the June quarter.<\/p>\n<p>Dr Reddy&#8217;s revenue fell 3.3% to Rs 8,854 crore and <strong>net profit<\/strong> fell 31.7% to Rs 913.2 crore. However, profit more than doubled from Rs 435.6 crore in Q1 FY27, which helps explain why the stock has held near its high.<\/p>\n<p>For <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong>, Sun Pharma&#8217;s fall came alongside growing sales, while Dr Reddy&#8217;s showed a sharp sequential recovery from a weak June quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_vs_Dr_Reddys_Outlook_After_the_Q2_Results\"><\/span><strong>Sun Pharma vs Dr Reddy&#8217;s Outlook After the Q2 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sun_Pharma_specialty_growth_and_margins\"><\/span><strong>Sun Pharma: specialty growth and margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharma&#8217;s FY26 revenue rose 12.7% to Rs 61,674 crore and <strong>net profit<\/strong> 5.3% to Rs 11,565 crore. Its outlook depends on <strong>specialty<\/strong> brand growth in the US and steady growth in India.<\/p>\n<p>The 10-point fall in <strong>operating margin<\/strong> in <strong>Q2 FY27<\/strong> is the number investors will watch most closely in the coming quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Reddys_rebuilding_after_a_product_cycle\"><\/span><strong>Dr Reddy&#8217;s: rebuilding after a product cycle<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Reddy&#8217;s FY26 net profit fell 27.4% to Rs 4,158 crore, as contributions from a large US generic product faded. Its recovery depends on new US launches, biosimilars and growth in India and emerging markets.<\/p>\n<p>In the <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> Q2 results debate, the market appears to be valuing Dr Reddy&#8217;s on the sequential recovery rather than the year-on-year fall.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Compare pharma stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_in_Sun_Pharma_vs_Dr_Reddys\"><\/span><strong>Risks in Sun Pharma vs Dr Reddy&#8217;s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Risks_for_Sun_Pharmaceutical_Industries\"><\/span><strong>Risks for Sun Pharmaceutical Industries<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharma&#8217;s main risk is that its margin does not recover from the Q2 FY27 drop. US regulatory action on plants and pricing pressure are ongoing risks. Promoters trimmed their stake from 54.48% to 52.68% and foreign institutions from 16.55% to 14.36%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Risks_for_Dr_Reddys_Laboratories\"><\/span><strong>Risks for Dr. Reddy&#x27;s Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> risk check, Dr Reddy&#8217;s faces generic price erosion and dependence on new launches. With its share price near the high and an ROE of 7.21%, expectations of a recovery are already priced in.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_vs_Dr_Reddys_Shareholding\"><\/span><strong>Sun Pharma vs Dr Reddy&#8217;s Shareholding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Sun Pharma vs Dr Reddy&#x27;s shareholding (Sep &#8217;26, change vs Sep &#8217;25)<\/th>\n<th>Sun Pharmaceutical Industries<\/th>\n<th>Dr. Reddy&#x27;s Laboratories<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>52.68% (-1.80 pts)<\/td>\n<td>26.63% (-0.01 pts)<\/td>\n<\/tr>\n<tr>\n<td>Foreign institutions (FII)<\/td>\n<td>14.36% (-2.19 pts)<\/td>\n<td>31.39% (-4.13 pts)<\/td>\n<\/tr>\n<tr>\n<td>Domestic institutions (DII)<\/td>\n<td>22.27% (+2.04 pts)<\/td>\n<td>31.88% (+3.90 pts)<\/td>\n<\/tr>\n<tr>\n<td>Public and others<\/td>\n<td>10.70% (+1.97 pts)<\/td>\n<td>10.10% (+0.24 pts)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Sun Pharma promoters hold 52.68%. Domestic institutions raised their stake from 20.23% to 22.27%.<\/p>\n<p>Dr Reddy&#8217;s promoters hold 26.63%. Domestic institutions raised their stake from 27.98% to 31.88%, while foreign institutions cut theirs from 35.52% to 31.39%. In <strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong>, domestic funds have been buying both stocks.<\/p>\n<p style=\"margin-top:24px;\"><strong>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Sun Pharma and Dr Reddy&#8217;s live and follow pharma sector research.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Which_Investor_Does_Each_Pharma_Stock_Suit\"><\/span><strong>Which Investor Does Each Pharma Stock Suit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sun_Pharma_suits_investors_who_want_specialty-led_growth\"><\/span><strong>Sun Pharma suits investors who want specialty-led growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Within Sun Pharma vs Dr Reddy&#x27;s, Sun Pharma fits investors who want the largest Indian drugmaker with a growing specialty business and higher ROE. They need to watch margins after the Q2 FY27 drop.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Reddys_suits_investors_betting_on_a_launch-led_recovery\"><\/span><strong>Dr Reddy&#8217;s suits investors betting on a launch-led recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Reddy&#8217;s fits investors who expect new launches to rebuild profit after FY26. They need to accept a low ROE and a stock already near its high.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_View_on_Sun_Pharma_vs_Dr_Reddys\"><\/span><strong>Final View on Sun Pharma vs Dr Reddy&#8217;s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Sun Pharma vs Dr Reddy&#x27;s<\/strong> shows two different readings of a weak quarter. Sun Pharma grew sales 11.8% but saw profit fall 36.2% on lower margins. Dr Reddy&#8217;s profit fell 31.7% year on year but more than doubled from Q1 FY27, and its stock sits near its high.<\/p>\n<p>Both trade at a <strong>P\/E<\/strong> of about 42. The Sun Pharma vs Dr Reddy&#x27;s outlook for 2027 depends on Sun Pharma&#8217;s margin recovery and Dr Reddy&#8217;s new launch pipeline.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Sun_Pharma_vs_Dr_Reddys\"><\/span><strong>FAQs on Sun Pharma vs Dr Reddy&#8217;s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Sun_Pharmas_profit_fall_in_Q2_FY27\"><\/span><strong>Why did Sun Pharma&#x27;s profit fall in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma&#x27;s net profit fell 36.2% to Rs 2,001.6 crore in Q2 FY27, even though revenue rose 11.8% to Rs 16,716 crore. Its operating margin dropped to 24.8% from 34.7%. Higher costs and a changing product mix weighed on profit. Profit was also below the June quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Dr_Reddys_stock_near_its_52-week_high_after_weak_results\"><\/span><strong>Why is Dr Reddy&#x27;s stock near its 52-week high after weak results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#x27;s closed at Rs 1,400.90 on 19 November 2026, about 1% below its 52-week high of Rs 1,414.90. Its Q2 FY27 profit fell 31.7% year on year to Rs 913.2 crore. However, profit more than doubled from Rs 435.6 crore in the June quarter. Investors appear to be focusing on that recovery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_has_the_higher_ROE\"><\/span><strong>Which pharma stock has the higher ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma has a return on equity of 13.79%, compared with 7.21% for Dr Reddy&#x27;s. Sun Pharma&#x27;s specialty brands support higher margins. Dr Reddy&#x27;s ROE fell as FY26 profit dropped 27.4%. Both companies carry little debt.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_of_Sun_Pharma_and_Dr_Reddys\"><\/span><strong>What is the P\/E of Sun Pharma and Dr Reddy&#x27;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma trades at a P\/E of 41.56 and Dr Reddy&#x27;s at 42.31 as of 19 November 2026. The pharma industry P\/E is 40.13. Both trade slightly above the sector. Their multiples are almost the same despite different profit trends.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_big_are_Sun_Pharma_and_Dr_Reddys\"><\/span><strong>How big are Sun Pharma and Dr Reddy&#x27;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma has a market cap of about Rs 4,56,593 crore, nearly four times Dr Reddy&#x27;s Rs 1,16,771 crore. Sun Pharma&#x27;s FY26 revenue was Rs 61,674 crore against Rs 35,059 crore for Dr Reddy&#x27;s. Sun Pharma&#x27;s FY26 net profit was Rs 11,565 crore and Dr Reddy&#x27;s was Rs 4,158 crore. Both are Nifty 50 companies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Sun_Pharma_and_Dr_Reddys\"><\/span><strong>Who owns Sun Pharma and Dr Reddy&#x27;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma&#x27;s promoters hold 52.68%, while Dr Reddy&#x27;s promoters hold 26.63%. Domestic institutions hold 22.27% of Sun Pharma and 31.88% of Dr Reddy&#x27;s. Foreign institutions hold 14.36% and 31.39% respectively. Domestic funds raised their stakes in both over the year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sun_Pharma_vs_Dr_Reddys_a_buy_or_sell_decision\"><\/span><strong>Is Sun Pharma vs Dr Reddy&#x27;s a buy or sell decision?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This Sun Pharma vs Dr Reddy&#x27;s comparison is educational and does not give a buy or sell call. Sun Pharma offers scale and a specialty business with margin pressure, while Dr Reddy&#x27;s offers a recovery case with a low ROE. Both trade near 42 times earnings. Investors should consult a SEBI-registered adviser before acting.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why did Sun Pharma's profit fall in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma's net profit fell 36.2% to Rs 2,001.6 crore in Q2 FY27, even though revenue rose 11.8% to Rs 16,716 crore. Its operating margin dropped to 24.8% from 34.7%. Higher costs and a changing product mix weighed on profit. Profit was also below the June quarter.\"}},{\"@type\":\"Question\",\"name\":\"Why is Dr Reddy's stock near its 52-week high after weak results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's closed at Rs 1,400.90 on 19 November 2026, about 1% below its 52-week high of Rs 1,414.90. Its Q2 FY27 profit fell 31.7% year on year to Rs 913.2 crore. However, profit more than doubled from Rs 435.6 crore in the June quarter. Investors appear to be focusing on that recovery.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock has the higher ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma has a return on equity of 13.79%, compared with 7.21% for Dr Reddy's. Sun Pharma's specialty brands support higher margins. Dr Reddy's ROE fell as FY26 profit dropped 27.4%. Both companies carry little debt.\"}},{\"@type\":\"Question\",\"name\":\"What is the P\/E of Sun Pharma and Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma trades at a P\/E of 41.56 and Dr Reddy's at 42.31 as of 19 November 2026. The pharma industry P\/E is 40.13. Both trade slightly above the sector. Their multiples are almost the same despite different profit trends.\"}},{\"@type\":\"Question\",\"name\":\"How big are Sun Pharma and Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma has a market cap of about Rs 4,56,593 crore, nearly four times Dr Reddy's Rs 1,16,771 crore. Sun Pharma's FY26 revenue was Rs 61,674 crore against Rs 35,059 crore for Dr Reddy's. Sun Pharma's FY26 net profit was Rs 11,565 crore and Dr Reddy's was Rs 4,158 crore. Both are Nifty 50 companies.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Sun Pharma and Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma's promoters hold 52.68%, while Dr Reddy's promoters hold 26.63%. Domestic institutions hold 22.27% of Sun Pharma and 31.88% of Dr Reddy's. Foreign institutions hold 14.36% and 31.39% respectively. Domestic funds raised their stakes in both over the year.\"}},{\"@type\":\"Question\",\"name\":\"Is Sun Pharma vs Dr Reddy's a buy or sell decision?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This Sun Pharma vs Dr Reddy's comparison is educational and does not give a buy or sell call. Sun Pharma offers scale and a specialty business with margin pressure, while Dr Reddy's offers a recovery case with a low ROE. Both trade near 42 times earnings. Investors should consult a SEBI-registered adviser before acting.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharma vs Dr Reddy&#8217;s 2027: both reported Q2 FY27 profit declines of more than 30%, but Dr Reddy&#8217;s trades within 1% of its 52-week high while Sun Pharma is about 7% below. A side-by-side data comparison.<\/p>\n","protected":false},"author":35,"featured_media":357361,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,7377,6686,18947,8498],"class_list":["post-357365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-dr-reddys-laboratories","tag-pharmaceuticals","tag-stock-comparison","tag-sun-pharmaceutical-industries"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["357361"],"rank_math_title":["Sun Pharma vs Dr Reddy&#x27;s 2027: Q2 Results and Valuation"],"rank_math_description":["Sun Pharma vs Dr Reddy&#x27;s 2027: Q2 FY27 results, margins, P\/E, ROE, specialty vs generics, shareholding and share price of two pharma leaders compared."],"rank_math_focus_keyword":["Sun Pharma vs Dr Reddy&#x27;s"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/sun-pharma-vs-dr-reddy-s-2027-profits-fell-over-30-at-both-yet-one-stock-sits.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/357365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=357365"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/357365\/revisions"}],"predecessor-version":[{"id":357366,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/357365\/revisions\/357366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/357361"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=357365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=357365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=357365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}